Fig. 2: PRMT1 mediates NONO arginine methylation in CRC cells.
From: PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer
a Compared to adjacent normal (N) tissue, PRMT1 mRNA level was higher in CRC tissue (T), as determined by qPCR (n = 29 paired tissues). There were no differences in PRMT3, PRMT4, and PRMT5 mRNA levels between groups. b PRMT1 protein is highly expressed in CRC tissue. PRMT5 protein expression was similar between T and N tissues, as determined by western blotting (n = 28 paired tissues; left panel). Protein band intensity was quantified using ImageJ software (right panel). c NONO and the aDMA modification colocalized in the nucleus. Immunofluorescence analysis was performed using anti-NONO and -ADMA antibodies (right panel) in KM12 and HCT8 cells, and colocalization was analyzed using ZEN v3.0 software (Zeiss, Oberkochen, Germany) (left panel). Scale bar, 10 μm. d, e PRMT1 silencing reduces NONO aDMA level. Endogenous NONO was immunoprecipitated (IP) from control and PRMT1-deficient KM12 and HCT8 cells and analyzed by western blotting (d). NONO methylation was detected using an anti-ADMA antibody. For Duolink PLA (e), NONO aDMA level was detected using anti-NONO and -ADMA antibodies (left panel). At least 100 nuclei were counted in each group (right panel). **P < 0.01, ***P < 0.001; ns no significance.
